Navigation Links
INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale
Date:10/30/2009

HONOLULU - October 29, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today. The primary objective of this study was to assess the change from baseline on the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) in patients ages 6 to 12 with a primary diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) with the presence of oppositional symptoms at baseline. INTUNIV met the primary objective demonstrating significant efficacy in reducing symptoms as measured by the oppositional subscale. Some of the symptoms measured by this scale include deliberately doing things that annoy others, refusing to comply with adults' requests, and being touchy or easily annoyed by others.

According to the Centers for Disease Control and Prevention (CDC), approximately 7.8 percent of all US school-aged children have been diagnosed with ADHD at some point in their lives. ADHD is a complex neurobehavioral disorder, which includes symptoms and behaviors such as inattentiveness, running around or climbing excessively, and being excitable or impulsive, many of which can be disruptive.

"The disruptive nature of ADHD can impact social and academic settings for those patients diagnosed with the disorder," said F. Randy Sallee, MD, PhD, Professor of Psychiatry at the University of Cincinnati and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. "This study showed that INTUNIV is an effective option for treating a range of ADHD symptoms."

INTUNIV, a once-daily formulation of guanfacine, was approved by the US Food and Drug Administration (FDA) on September 2, 2009 as the first selective alpha-2A agonist for the treatment of ADHD. Although the mechanism of action is not known, guanfacine, the active ingredient in INTUNIV, is thought to sel
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Shires INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
2. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
3. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
4. Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products
5. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
6. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
9. How embryonic stem cells develop into tissue-specific cells demonstrated
10. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
11. Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... 2015 Omar Ahmad Barrada, a junior ... in the 2015 Congress of Future Medical Leaders in ... gathering of “America’s highest achieving high school students.” , ... set new goals and learn better study habits,” said ... during which we can ask the surgeons questions.” , ...
(Date:5/22/2015)... May 22, 2015 Combination therapy, ... option for chronic obstructive pulmonary disorder (COPD) as ... and AstraZeneca plc as well as Germany’s Boehringer ... and position. But will market payers, clinicians and ... well-entrenched products to completely new ones? , In ...
(Date:5/22/2015)... 22, 2015 Hands On HealthCare Massage ... 2015, the Annual One Day Sale on Massage ... On HCMT offers drastically reduced certificates one day a year. ... enough sessions, through what used to be the slowest time ... the community as well. This once a year occurrence has ...
(Date:5/22/2015)... 2015 “It’s like learning an ... CHHRP-QT, Vice President of Clinical Operations/Education and Training ... that impacts how care is coded and reimbursed.” ... term care reimbursement, operations and compliance consulting, as ... management, launches a new series of day-long seminars ...
Breaking Medicine News(10 mins):Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... more attention to choosing the doctor, not the device ... as a safe and long-lasting way to alleviate hip-related ... fails, the problem more often lies with surgical error ... , , Dislocation of the implant was the most common ...
... gene is a key to understanding, and perhaps killing, ... only to reawaken years later, researchers at The University ... the December Journal of Clinical Investigation . , ... ARHI acts as a switch for autophagy, or self-cannibalization, ...
... that Lewy bodies, clumps of aggregated proteins inside ... Parkinson,s disease and other neurodegenerative diseases. , The ... protein recycling and waste disposal, leading to the ... cells? , One possible answer: by breaking a ...
... supplementation was found to be effective in relieving pain ... chronic pancreatitis (CP), reports a new study in ... the pancreas in which patients experience abdominal pain (in ... Pain is the major problem in 90 percent of ...
... from presence of salicylic acid in study participants , , ... key component that gives aspirin its anti-inflammatory and pain-relieving ... own, a new study suggests. , Salicylic acid (SA) ... who had not taken aspirin recently -- especially vegetarians. ...
... organ improved odds, study shows , , WEDNESDAY, Dec. 31 ... donated kidney raised the chances of a successful transplant ... European researchers report. , The study, published in the ... of Medicine , got generally favorable reviews from American ...
Cached Medicine News:Health News:Surgeons Often Are Blamed When Hip Replacements Fail 2Health News:Surgeons Often Are Blamed When Hip Replacements Fail 3Health News:Dormant cancer cells rely on cellular self-cannibalization to survive 2Health News:Toxicity mechanism identified for Parkinson's disease 2Health News:Antioxidants offer pain relief in patients with chronic pancreatitis 2Health News:A Better Method of Kidney Storage 2Health News:A Better Method of Kidney Storage 3
(Date:5/22/2015)... BOTHELL, Wash. , May 22, 2015  BioLife Solutions, ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues ("BioLife" or the "Company"), ... 2015 Marcum MicroCap Conference. The Company is ... on Wednesday, May 27, 2015 at the Grand Hyatt Hotel ...
(Date:5/22/2015)... 22, 2015 The Assistance Fund announces the ... provides financial assistance for copay to individuals diagnosed with ... the addition of the Melanoma Copay Assistance Program to ... , executive director. "With each additional program we are ... world where no one is denied access to medications ...
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2The Assistance Fund Adds Melanoma Assistance Program 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
... of New Anti-TNF Therapy in Three Rheumatic Diseases with ... KENILWORTH, N.J., June 26 Centocor Ortho Biotech Inc. ... today that the Committee for Medicinal Products for Human ... a positive opinion recommending the approval of SIMPONI(TM) (golimumab) ...
... Once-Daily Treatment of Pseudomonas Lung Infections , , ... Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis ... Inc., for the continued development of ARIKACE(TM) (liposomal amikacin ... Pseudomonas lung infections in cystic fibrosis (CF) and ...
Cached Medicine Technology:SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4
... superb field flatness, high UV transmission ... extra long working distances, these objectives ... with inverted microscopes. Because of their ... ELWD DM,objectives can be used universally ...
Inquire...
... Axiovert 40 inverted microscope ... have ever expected from a microscope in this ... quality, and functionality. Axiovert 40 has been designed ... as possible thus increasing the efficiency of ...
... is an advanced inverted microscope ... exclusive CFI60 optical system yields ... aperatures and longer working distances. ... to take full advantage of ...
Medicine Products: